Intranasal Heparin Tolerability Study

Summary

Intranasal Heparin Tolerability Study is a clinical trial^[1].

Key Facts

• Intranasal Heparin Tolerability Study is in the country of United States^[2].
• Intranasal Heparin Tolerability Study's instance of is recorded as clinical trial^[3].
• Intranasal Heparin Tolerability Study's start time is recorded as +2020-08-31T00:00:00Z^[4].
• Intranasal Heparin Tolerability Study's end time is recorded as +2020-09-30T00:00:00Z^[5].
• Intranasal Heparin Tolerability Study's sponsor is recorded as University of Mississippi^[6].
• Intranasal Heparin Tolerability Study's number of participants is recorded as {'unit': '1', 'amount': '+6'}^[7].
• Intranasal Heparin Tolerability Study's title is recorded as Intranasal Heparin Tolerability Study^[8].
• Intranasal Heparin Tolerability Study's uses is recorded as partial thromboplastin time^[9].
• Intranasal Heparin Tolerability Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Intranasal Heparin Tolerability Study's ClinicalTrials.gov ID is recorded as NCT04490239^[11].
• Intranasal Heparin Tolerability Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[12].
• Intranasal Heparin Tolerability Study's research intervention is recorded as Heparin calcium^[13].
• Intranasal Heparin Tolerability Study's research intervention is recorded as nadroparin calcium^[14].
• Intranasal Heparin Tolerability Study's clinical trial phase is recorded as phase I clinical trial^[15].
• Intranasal Heparin Tolerability Study's research subject recruitment status is recorded as not yet recruiting^[16].
• Intranasal Heparin Tolerability Study's study type is recorded as interventional study^[17].